Consistent with this finding, lung cancers harbouring the KRAS G12D substitution were recently associated with a lower tumour mutation burden [117,118], for which reason this mutation may serve as a negative biomarker for the success of immunotherapy. This evidence concerns the gene KRAS and lung carcinoma.